ARBUTUS BIOPHARMA CORP's ticker is ABUS and the CUSIP is 03879J100. A total of 91 filers reported holding ARBUTUS BIOPHARMA CORP in Q2 2021. The put-call ratio across all filers is 1.48 and the average weighting 0.0%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $105,899 | -11.7% | 52,167 | 0.0% | 0.00% | – |
| Q2 2023 | $119,984 | -6.1% | 52,167 | +23.7% | 0.00% | – |
| Q1 2023 | $127,748 | +30.0% | 42,161 | 0.0% | 0.00% | – |
| Q4 2022 | $98,235 | +22.5% | 42,161 | +0.4% | 0.00% | – |
| Q3 2022 | $80,207 | -32.3% | 41,993 | -3.9% | 0.00% | – |
| Q2 2022 | $118,462 | +10.2% | 43,713 | +21.1% | 0.00% | – |
| Q1 2022 | $107,530 | -35.6% | 36,084 | -16.1% | 0.00% | – |
| Q4 2021 | $167,000 | -15.7% | 42,985 | -7.0% | 0.00% | – |
| Q3 2021 | $198,000 | +33.8% | 46,204 | -5.4% | 0.00% | – |
| Q2 2021 | $148,000 | +59.1% | 48,865 | +86.6% | 0.00% | – |
| Q1 2019 | $93,000 | +121.4% | 26,188 | +140.4% | 0.00% | – |
| Q4 2018 | $42,000 | -81.2% | 10,892 | -53.7% | 0.00% | – |
| Q3 2018 | $223,000 | +2.3% | 23,506 | -21.4% | 0.00% | – |
| Q2 2018 | $218,000 | – | 29,896 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Whitefort Capital Management, LP | 11,895,477 | $24,147,818 | 12.66% |
| Two Seas Capital LP | 8,280,818 | $16,810,061 | 3.38% |
| FourWorld Capital Management LLC | 1,341,907 | $2,724,071 | 0.51% |
| Tejara Capital Ltd | 180,077 | $365,556 | 0.21% |
| Woodline Partners LP | 4,719,903 | $9,581,403 | 0.11% |
| Hudson Bay Capital Management LP | 8,299,808 | $16,848,610 | 0.07% |
| Kepos Capital LP | 155,691 | $316 | 0.06% |
| Virtus ETF Advisers LLC | 40,040 | $81,281 | 0.05% |
| Centiva Capital, LP | 1,071,705 | $2,175,561 | 0.05% |
| Kades & Cheifetz LLC | 20,000 | $40,600 | 0.03% |